scholarly journals Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS‐CoV‐2

2020 ◽  
Vol 93 (1) ◽  
pp. 533-536 ◽  
Author(s):  
Eddie Chi‐man Leung ◽  
Viola Chi‐ying Chow ◽  
May Kin‐ping Lee ◽  
Raymond Wai‐man Lai
Keyword(s):  
2021 ◽  
Author(s):  
Huifeng Shen ◽  
David Forgacs ◽  
Digantkumar Chapla ◽  
Kelley W. Moremen ◽  
Lance Wells ◽  
...  

AbstractThe SARS-CoV-2 pandemic and the vaccination effort that is ongoing has created an unmet need for accessible, affordable, flexible and precise platforms for monitoring the induction, specificity and maintenance of virus-specific immune responses. Herein we validate a multiplex (Luminex-based) assay capable of detecting SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type (e.g. plasma, serum, saliva or blood spots). The well-established precision of Luminex-based assays provides the ability to follow changes in antibody levels over time to many antigens, including multiple permutations of the most common SARS-CoV-2 antigens. This platform can easily measure antibodies known to correlate with neutralization activity as well as multiple non-SARS-CoV-2 antigens such as vaccines (e.g. Tetanus toxoid) or those from frequently encountered agents (influenza), which serve as stable reference points for quantifying the changing SARS-specific responses. All of the antigens utilized in our study can be made in-house, many in E. coli using readily available plasmids. Commercially sourced antigens may also be incorporated and newly available antigen variants can be rapidly produced and integrated, making the platform adaptable to the evolving viral strains in this pandemic.Brief SummaryA multi-antigen assay for monitoring SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type was developed.


2020 ◽  
Vol 58 (4) ◽  
pp. 527-532 ◽  
Author(s):  
Jee-Soo Lee ◽  
Miyoung Kim ◽  
Moon-Woo Seong ◽  
Han-Sung Kim ◽  
Young Kyung Lee ◽  
...  

AbstractBackgroundChoosing the specimen type is the first step of the pre-analytical process. Previous reports suggested plasma as the optimal specimen for circulating tumor DNA (ctDNA) analysis. However, head-to-head comparisons between plasma and serum using platforms with high analytical sensitivity, such as droplet digital polymerase chain reaction (ddPCR), are limited, and several recent studies have supported the clinical utility of serum-derived ctDNA. This study aimed to compare the DNA profiles isolated from plasma and serum, characterize the effects of the differences between specimens on ctDNA measurement, and determine the major contributors to these differences.MethodsWe isolated cell-free DNA (cfDNA) from 119 matched plasma/serum samples from cancer patients and analyzed the cfDNA profiles by DNA fragment sizing. We then assessed KRAS mutations in ctDNA from matched plasma/serum using ddPCR.ResultsThe amount of large DNA fragments was increased in serum, whereas that of cfDNA fragments (<800 bp) was similar in both specimens. ctDNA was less frequently detected in serum, and the KRAS-mutated fraction in serum was significantly lower than that in plasma. The differences in ctDNA fractions between the two specimen types correlated well with the amount of large DNA fragments and white blood cell and neutrophil counts.ConclusionsOur results provided detailed insights into the differences between plasma and serum using DNA fragment sizing and ddPCR, potentially contributing to ctDNA analysis standardization. Our study also suggested that using plasma minimizes the dilution of tumor-derived DNA and optimizes the sensitivity of ctDNA analysis. So, plasma should be the preferred specimen type.


2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S590-S590
Author(s):  
Muhammad Ahmad ◽  
Annaliza Adaya ◽  
Dipika Patel ◽  
Robert Benirschke ◽  
Hong Lee
Keyword(s):  

2008 ◽  
Vol 62 (6) ◽  
pp. 1451-1461 ◽  
Author(s):  
S. P. Kuster ◽  
C. Ruef ◽  
R. Zbinden ◽  
J. Gottschalk ◽  
B. Ledergerber ◽  
...  

2001 ◽  
Vol 39 (1) ◽  
pp. 375-376 ◽  
Author(s):  
M. A. Riddell ◽  
D. Chibo ◽  
H. A. Kelly ◽  
M. G. Catton ◽  
C. J. Birch

2016 ◽  
Vol 85 (7-8) ◽  
Author(s):  
Miha Lučovnik ◽  
Nataša Tul Mandić ◽  
Jana Lozar Krivec ◽  
Urša Dolinar ◽  
Samo Jeverica

AbstractBackground: Streptococcus agalactiae is the leading cause of preventable invasive neonatal infections. Detection of maternal colonisation and use of antimicrobial prophylaxis during labour is a standard preventative approach. Very few data about the prevalence of colonisation with S. agalactiae among pregnant women in Slovenia are available.Methods: We performed a retrospective study of consecutive samples from pregnant women screened for S. agalactiae colonisation with enrichment culture during the period 2013-2014. Basic demographic data, specimen type, timing and result of the assay were analysed. Cumulative antimicrobial susceptibility for the positive samples was calculated.  Results: During 2 years study period 1564 pregnant women were tested. Mean age 31 years (18-46 years). Among samples received, majority were vaginal swabs 57,0 % (n=893). Recommended combined vaginal-rectal swabs were received in 12,9 % (n=192). Overall prevalence of maternal colonisation was 17,1 % (n=268) and did not differ with regard to specimen type. Resistance or reduced susceptibility to erythromycin and clindamycin was 23,1 % (n=62) and 20,9 % (n=56), respectively. No resistance to penicillin and vancomycin was detected.Conclusions: Few pregnant women get screened for S. agalactiae in Slovenia. Nevertheless, high colonisation rate was detected on a large sample size. Most samples were taken during the proposed period between 35-37 week of pregnancy. Recommended combined vaginal-rectal were less frequently taken for screening than vaginal swabs only. Penicillin and vancomycin remains universally active against S. agalactiae. However, erythromycin and clindamycin resistance was high.


Sign in / Sign up

Export Citation Format

Share Document